Mifepristone

Major

Mifepristone Arsenic Trioxide Injection Trisenox Increased risk of QT-interval prolongation and torsade de pointes Details Mifepristone Asciminib Scemblix Increased miFEPRIStone exposure and an increased asciminib exposure Details Mifepristone Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Mifepristone Atogepant Qulipta Increased atogepant exposure Details Mifepristone Avapritinib Ayvakit Increased avapritinib exposure and increased incidence and severity of adverse reactions Details Mifepristone Avatrombopag Doptelet Increased CYP3A4 substrate exposure Details Mifepristone Azithromycin AzaSite Increased miFEPRIStone exposure and an increased risk of QT interval prolongation Details Mifepristone Belumosudil Rezurock Explained Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Bicalutamide Casodex Increased miFEPRIStone exposure Details Mifepristone Atorvastatin Atorvaliq Increased CYP3A4 substrate exposure and an increased miFEPRIStone exposure Details Mifepristone Cariprazine Vraylar Explained Increased exposure to cariprazine and its active metabolite, didesmethylcariprazine Details Mifepristone Abiraterone Abirtega Increased CYP3A4 substrate exposure Details Mifepristone Alfuzosin UroXatral Increased CYP3A4 substrates exposure and an increased risk of QT interval prolongation Details Mifepristone Amlodipine Amvaz® Increased miFEPRIStone exposure, an increased amLODIPine exposure and an increased risk of hypotension and edema Details Mifepristone Anagrelide Agrylin Increased risk of QT interval prolongation Details Mifepristone Avanafil Stendra Increased CYP3A4 substrate exposure Details Mifepristone Bedaquiline Sirturo Increased bedaquiline exposure and an increased risk of QT interval prolongation Details Mifepristone Brexpiprazole Rexulti Increased brexpiprazole exposure Details Mifepristone Brodalumab Injection Siliq Increased miFEPRIStone exposure Details Mifepristone Cabozantinib Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Mifepristone Cabozantinib (Thyroid Cancer) Cabometyx Increased cabozantinib exposure and an increased risk of cabozantinib-related adverse reactions Details Mifepristone Capmatinib Tabrecta Increased CYP3A4 substrate exposure Details Mifepristone Chloroquine Aralen® An increased risk of QT interval prolongation Details Mifepristone Clotrimazole Aardora Anti-Fungal Maximum Strength Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Lozenge Mycelex® Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Topical Cruex Antifungal Increased miFEPRIStone exposure Details Mifepristone Clotrimazole Vaginal Gyne-Lotrimin 3® Cream Increased miFEPRIStone exposure Details Mifepristone Dabigatran Pradaxa® Increased dabigatran exposure and an increased risk of bleeding Details Mifepristone Dabigatran Etexilate Increased dabigatran exposure and an increased risk of bleeding Details Mifepristone Darolutamide Nubeqa Increased CYP3A4 substrate exposure Details Mifepristone Degarelix Injection Firmagon Increased risk of QT interval prolongation Details Mifepristone Deutetrabenazine Austedo An increased risk of QT interval prolongation Details Mifepristone Diazepam Nasal Spray Valtoco Increased CYP3A4 substrate exposure Details Mifepristone Diazepam Rectal Diastat Increased CYP3A4 substrate exposure Details Mifepristone Digoxin Cardoxin® Increased digoxin exposure Details Mifepristone Disopyramide Norpace Increased disopyramide exposure and an increased risk of QT interval prolongation Details Mifepristone Dolasetron Anzemet An increased risk of QT interval prolongation Details Mifepristone Dolasetron Injection Anzemet An increased risk of QT interval prolongation Details Mifepristone Dolutegravir Juluca® (as a combination product containing dolutegravir, rilpivirine) Increased CYP3A4 substrate exposure Details Mifepristone Doravirine Pifeltro Increased CYP3A4 substrate exposure Details